EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study

Daniel Weiss iD, Wolfgang H Jost iD, József Attila Szász, Zvezdan Pirtošek, Ivan Milanov, Volker Tomantschger, Norbert Kovács, Harry Staines, Bharat Amlani, Niall Smith, Teus van Laar iD

Movement Disorders Clinical Practice · 2025-08 · 12 (8) · 1075-1085

DOI: 10.1002/mdc3.70046 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 25.03.2025. Verfasst von Daniel Weiss und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department for Neurodegenerative Diseases, Centre for Neurology, Hertie-Institute for Clinical Brain Research, Tübingen, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Carbidopa, Levodopa, Antiparkinson Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Britannia Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced in 2018 as a device‐aided therapy for advanced Parkinson's disease (PD).

Objectives

The ELEGANCE study (NCT05043103) is gathering real‐world data on long‐term efficacy, safety and patient‐reported outcomes with LECIG from 13 European countries. This article reports data from the planned interim analysis.

Methods

The study enrolled patients prescribed LECIG as part of routine clinical care. We evaluated patients at V1 before starting LECIG treatment (in seven patients V1 data were obtained retrospectively), and thereafter at V2 (3–6 months) or V3 (6–12 months).

Results

This analysis includes 167 patients from 37 centers. Three patients from this analysis set (1.8%) discontinued the study. Mean (±SD) daily OFF‐time hours (MDS‐UPDRS IV item 4.3) were substantially reduced by 3.47 ± 3.56 h at V2 (baseline: 5.15 ± 3.05; P < 0.0001). Similarly, MDS‐UPDRS part IV total scores were reduced by 4.24 ± 4.08 at V2 (baseline: 10.77 ± 3.83); ( P = 0.0001) and MDS‐UPDRS part II scores by 3.63 ± 7.76 at V2 (baseline: 20.65 ± 8.17; P = 0.0004). PDSS‐2 total scores were sustainably improved (reduction of 7.38 ± 10.72 at V2 [baseline: 25.21 ± 10.62]; P < 0.0001), as was the PDQ‐8 summary index score indicating an improvement in quality of life (QoL) (reduction of 13.3 ± 19.05 at V2 [baseline: 46.34 ± 20.09]; P < 0.0001). For all parameters improvements were maintained at V3. Patient‐reported satisfaction with the LECIG pump was high. Most adverse events were related to the procedure or the device.

Conclusions

Routine use of LECIG for up to 12 months provided sustained control of motor symptoms, and was well tolerated with a positive impact on QoL and high patient satisfaction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseCarbidopaLevodopaAntiparkinson AgentsCatecholsNitrilesHumansMaleFemaleDrug CombinationsAgedMiddle AgedTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

advanced Parkinson's diseasecarbidopa intestinal gelclinical practiceentacaponelevodopa

Substanzen

CarbidopaLevodopaDrug CombinationsAntiparkinson Agentscarbidopa, levodopa drug combinationCatecholsentacaponeNitriles

Autor:innen und Institutionen

  • Department for Neurodegenerative Diseases, Centre for Neurology, Hertie-Institute for Clinical Brain Research, Tübingen, Germany.
  • Parkinson-Klinik Ortenau, Wolfach, Germany.
  • Department of Neurology, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, Romania.
  • Department of Neurology, University Medical Centre and Faculty of Medicine, Ljubljana, Slovenia.
  • University Neurological Hospital "St. Naum", Sofia, Bulgaria.
  • Gailtal-Klinik Hermagor, Neurorehabilitation, Austria.

ORCID-Profile: Daniel Weiss, Wolfgang H Jost, Teus van Laar

Förderung

  • Britannia Pharmaceuticals

Zitieren

APA

Weiss, D., Jost, W. H., Szász, J. A., Pirtošek, Z., Milanov, I., Tomantschger, V., Kovács, N., Staines, H., Amlani, B., Smith, N., & van Laar, T. (2025). Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study. Movement Disorders Clinical Practice, 12(8), 1075-1085. https://doi.org/10.1002/mdc3.70046

Vancouver

Weiss D, Jost WH, Szász JA, Pirtošek Z, Milanov I, Tomantschger V, et al. Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study. Movement Disorders Clinical Practice. 2025;12(8):1075-1085. doi:10.1002/mdc3.70046

BibTeX
@article{Weiss2025,
  author = {Weiss, Daniel and Jost, Wolfgang H and Szász, József Attila and Pirtošek, Zvezdan and Milanov, Ivan and Tomantschger, Volker and Kovács, Norbert and Staines, Harry and Amlani, Bharat and Smith, Niall and van Laar, Teus},
  title = {Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study},
  journal = {Movement Disorders Clinical Practice},
  year = {2025},
  volume = {12},
  number = {8},
  pages = {1075--1085},
  doi = {10.1002/mdc3.70046}
}
Kostenlos starten →